Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 12 Nov 2026
Promising but preliminary

HSA-coated intrinsically radiolabeled [(177)Lu]Lu₂O₃ nanoparticles for injectable nanoscale brachytherapy: Preclinical validation and first-in-human imaging.

Injectable nanoparticles designed for targeted radiation showed promising tumor targeting in animals and early feasibility in initial human imaging.

This preclinical validation with first-in-human imaging feasibility examined HSA-coated intrinsically radiolabeled [(177)Lu]Lu₂O₃ nanoparticles for injectable nanoscale brachytherapy: Preclinical validation and first-in-human imaging. The nanoparticle platform showed preclinical tumor retention and dosimetry feasibility plus first-in-human imaging, supporting further study of injectable nanoscale brachytherapy.

What the study was

Study design
Preclinical validation with first-in-human imaging feasibility
Category
Drug Development
Maturity
Exploratory
Journal
Nanomedicine : nanotechnology, biology, and medicine

Why it surfaced

Retained after review of PubMed metadata and abstract because its preclinical validation with first-in-human imaging feasibility directly informs novel therapeutics; scoring was capped conservatively for design and evidence maturity.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.